Deltex Medical announces launch of its next generation monitoring system in UK and EU
West Sussex-based Deltex Medical Group has launched its next generation monitoring device - the TrueVue system - in the UK and EU and expects revenue from its sales to begin in November this year.
The company said the lightweight and portable TrueVue System, now CE marked, was a "major advance" over its existing system.
It is expected to be used in adult and paediatric patients undergoing surgery, including in accident and emergency (A&E)) or in critical care departments such as intensive care units (ICU) or high dependency units (HDU).
Visit Hampshire Biz News for bright, upbeat and positive business news from the county
Deltex said it could now deploy the device for in-hospital evaluations to ensure there are no teething issues with the launch. It will not fulfil any orders until this process is completed - expected to take around three months.
Andy Mears, CEO of the company, said: "We are delighted that we have launched the new next generation TrueVue System. This is against the challenging backdrop of having to conduct work on this project through Covid-19 and dealing with the associated supply chain issues.
"I want to thank all of our employees for their hard work and resilience to get this completed.
"Initial interest in the new monitor has been positive and we expect the launch to help increase activity levels in all territories ahead of other international regulatory approvals being obtained. We have been manufacturing new monitors in anticipation of starting to fulfil orders in November."
The new TrueVue System will also be the platform for Deltex's new non-invasive Suprasternal device, which is currently under development and aimed at the awake patient market.
It has significantly broader applications than the current invasive device, such as in A&E, general wards and by paramedics, the company noted.
Deltex Medical aims to drive recurring revenues with the sale of single-use disposable oesophageal doppler monitoring (ODM) probes, which are used in the TrueVue System and to complement these revenues with new revenue to be derived from its new non-invasive technology.
